登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C21H31O5N3 · 2H2O
化学文摘社编号:
分子量:
441.52
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
产品名称
赖诺普利, United States Pharmacopeia (USP) Reference Standard
InChI
1S/C21H31N3O5.2H2O/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15;;/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29);2*1H2/t16-,17-,18-;;/m0../s1
SMILES string
[H]O[H].[H]O[H].NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O
InChI key
CZRQXSDBMCMPNJ-ZUIPZQNBSA-N
grade
pharmaceutical primary standard
API family
lisinopril
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
human ... ACE(1636)
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
血管紧张素转换酶（ACE）抑制剂。
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Application
Lisinopril USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Lisinopril and Hydrochlorothiazide Tablets
- Lisinopril Compounded Oral Suspension
- Lisinopril Tablets
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
signalword
Danger
hcodes
Hazard Classifications
Repr. 1A - STOT RE 2
target_organs
Kidney
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Stephen J Bright et al.
Australasian journal on ageing, 34(1), 33-37 (2013-10-15)
The Alcohol-Related Problems Survey (ARPS) reliably classifies drinking as non-hazardous, hazardous or harmful using scoring algorithms that consider quantity and frequency of alcohol use alone and in combination with health conditions, medication-use and functional status. Because it has been developed
T D Giles
Zeitschrift fur Kardiologie, 80 Suppl 2, 35-39 (1991-01-01)
Data from the lisinopril-captopril comparison trial (6), as well as other data (1, 8, 14, 10) indicate that both long- and short-acting ACEI are effective and safe for the treatment of CHF. An improved effect on LV function and signs
C Valenzuela et al.
General pharmacology, 25(5), 825-832 (1994-09-01)
1. The effects of lisinopril, an angiotensin-converting enzyme inhibitor, were studied on cardiac contractile force, action potential characteristics and membrane ionic currents. 2. In guinea-pig atria, lisinopril (0.001-1 microM) exerted a negative inotropic effect which was accompanied by a shortening
M C Nzerue
The Central African journal of medicine, 38(9), 391-392 (1992-09-01)
A case of angioedema induced by antihypertensive therapy with lisinopril is presented. The patient was a 70 year old black woman, with a history of hypertension for 15 years. The patient presented with acute onset of swelling involving the oro-facial
K Simpson et al.
Drugs, 59(5), 1149-1167 (2000-06-14)
The ACE inhibitor lisinopril is a lysine derivative of enalaprilat, the active metabolite of enalapril. In patients with heart failure, maximum pharmacodynamic effects are produced 6 to 8 hours after administration of the drug and persist for 12 to 24
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持